Product Development Pipeline

Diabetes

Technosphere® Insulin
MannKind’s lead investigational product candidate is currently in Phase 3 clinical trials in the U.S., Europe and Latin America, to study its safety and efficacy in the treatment of type 1 and type 2 diabetes. Because the product has been found to produce a profile of insulin levels in the bloodstream that mimics the insulin profile normally seen in healthy individuals immediately following the beginning of the meal, researchers believe that the Technosphere® Insulin System may have the potential to change the way diabetes is treated. The potential use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease and is currently be explored.

Cancer

MKC-1106-PP
MannKind is also developing therapies for the treatment of cancer. The lead product candidate in this program, MKC-1106-PP is an active immunotherapy regimen intended for the treatment of several solid-tumors, including ovarian, colorectal, pancreatic, renal, breast and prostate     carcinomas.

MKC1106-PP consists of three components:

• a DNA plasmid that encodes two tumor-associated antigens, known as PRAME and PSMA;
• and two synthetic peptides, one an analog of PRAME and one an analog of PSMA.

Mannkind commenced a Phase 1 clinical trial for MKC-1106-PP in January 2007.